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Staphylococcus aureus is a major human pathogen, and a leading cause of soft tissue
and blood stream infections. One of the causes of its success as a pathogen is the
peculiar array of immune evasion factors through which the bacterium avoids host
defenses, where the staphylococcal protein A (SpA) plays a major role thanks to its
IgG binding activities. Moreover, SpA has recently been proposed as a promising
vaccine antigen. In this study, we evaluated the expression of SpA in a collection of
staphylococcal strains, about 7% of which did not express SpA (SpA− strains), despite
the presence of the gene. By a comparative genomic analysis, we identified that a
mutation in the spa 5′ UTR sequence affecting the RBS is responsible for the loss of SpA
in a subset of SpA− strains. Using a high-throughput qRT-PCR approach on a selected
panel of virulence-related genes, we identified that the SpA− phenotype is associated
with lower spa transcript levels and increased expression and production of capsule
as well as other changes in the transcription of several key virulence factors. Our data
suggest that the SpA− phenotype has occurred in geographically distinct strains through
different molecular mechanisms including both mutation, leading likely to translation
alterations, and transcriptional deregulation. Furthermore, we provide evidence that
SpA− strains are highly susceptible to phagocytic uptake mediated by anti-capsule
antibodies. These data suggest that S. aureus may alter its virulence factor expression
pattern as an adaptation to the host or environment. Vaccination strategies targeting
both SpA and capsule could therefore result in broader coverage against staphylococcal
isolates than SpA alone.
Keywords: Staphylococcus aureus, protein A, capsule, transcription profiling, vaccines
INTRODUCTION
Staphylococcus aureus is a Gram-positive bacterium that colonizes the human nares and skin
(Kluytmans et al., 1997; Wertheim et al., 2005). It is a frequent cause of opportunistic
infections that lead to a huge variety of diseases, ranging from skin and soft tissue infection
to infective endocarditis and bacteremia (Tong et al., 2015). The success of this bacterium as a
pathogen is directly linked to its array of virulence and immune evasion factors that enable the
bacterium to escape host defenses. These include factors able to block the complement cascade,
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impair neutrophil chemotaxis, inhibit opsonophagocytosis and
kill immune host cells (Foster, 2005). Among them, a central
role is played by the Staphylococcal protein A (SpA), a cell
wall-associated protein that can either be expressed on the
surface of the bacterium or be secreted. SpA usually contains
five repeated domains responsible for two distinct antibody
binding activities. Its ability to bind IgGs through the Fc portion
can prevent opsonophagocytosis by sequestering antibodies and
by displaying them on the bacterial surface in an incorrect
orientation (Peterson et al., 1977; Falugi et al., 2013). Moreover,
SpA can also bind the VH3 domain of B cell receptors acting
as a superantigen, thus leading to an impairment of the B
cell response (Levinson et al., 1995; Silverman and Goodyear,
2006). In addition to SpA, several other staphylococcal proteins
contribute to the bacterium’s ability to avoid the host immune
system, and often have redundant or overlapping functions. For
example, the staphylococcal immunoglobulin-binding protein
(Sbi), a surface protein that also binds the Fc of immunoglobulins
(Zhang et al., 1998), as well as capsular polysaccharide, Clumping
Factor A (ClfA) and others, contribute to the inhibition of
opsonophagocytosis, through different mechanisms (Thakker
et al., 1998; Foster, 2005; Rooijakkers et al., 2005; Higgins et al.,
2006; Smith et al., 2011; Kuipers et al., 2016). It is interesting
to note that S. aureus employs multiple strategies to accomplish
a single task, and considering this redundancy, it is likely that
none of these factors is strictly essential for virulence. In fact,
infection-related clinical isolates may naturally be deficient in
a range of these factors (Peacock et al., 2002; Boyle-Vavra
et al., 2015). Furthermore, animal model studies comparing
virulence of isogenic single mutants showed attenuation but did
not completely abolish the pathogen’s ability to infect (Patel
et al., 1987; Moreillon et al., 1995; Thakker et al., 1998). One
important observation is that each of these virulence factors has
a particular temporal expression profile under in vitro growth
conditions, reflecting a different expression during the distinct
phases of infection (Cheung et al., 2004). As a general rule,
factors involved in colonization (cell wall-associated proteins
with adhesive and tissue-binding functions) are preferentially
expressed during the exponential phase of an in vitro growth
curve, while proteins involved in dissemination and spreading
of the infection (exoproteins, proteases, toxins, haemolysins) are
more likely to be expressed in the stationary phase (Cheung et al.,
2004). This expression profile is the result of a highly complex and
interconnected regulation that enables the pathogen to respond
to external stimuli and environmental changes (Wang and Muir,
2016; Haag and Bagnoli, 2017). Another example of the plasticity
of this pathogen resides in its ability to acquire new antibiotic
resistance and virulence traits through horizontal gene transfer,
making staphylococcal infections increasingly difficult to treat
(Chambers and Deleo, 2009; DeLeo et al., 2010; Foster, 2017).
For all these reasons, a vaccine against S. aureus would have an
extremely beneficial impact on public health. Several attempts
have been made for the development of a S. aureus vaccine
and a number of investigative formulations have been developed
in both preclinical and clinical phases of research (Fattom
et al., 2004; McNeely et al., 2014). Despite the efforts, none has
been licensed to date (Proctor, 2012; Spellberg and Daum, 2012;
Giersing et al., 2016). In recent years, SpA has been proposed
as a promising vaccine candidate, showing efficacy in passive
immunization and animal models (Kim et al., 2012, 2015; Falugi
et al., 2013; Varshney et al., 2018). In murine models, the
vaccination with a mutated form of the protein lacking the IgG
binding activities elicited high titers of SpA-specific antibodies
(Kim et al., 2010). Moreover, immunization of mice with
this mutated protein protected from infection in a subsequent
challenge with S. aureus USA300, determining also an increase in
the IgG titers of other staphylococcal antigens as compared with
non-immunized control animals (Kim et al., 2010).
Considering the central role of SpA in staphylococcal
pathogenesis and the rising interest in SpA as potential
vaccine antigen, in the present study we aimed to understand
the prevalence of SpA expression in a large collection of
staphylococcal isolates. We identified a subset of strains carrying
the gene but lacking expression to detectable levels of SpA
(SpA− strains). We investigated whether the absence of SpA
is associated with genetic polymorphisms common to the
SpA− subset of strains, and whether other changes in the
virulence gene expression profile are associated with the SpA−
phenotype, highlighting a profound interconnectedness of SpA
and other immune evasion factors. Understanding how different
staphylococcal immune evasion mechanisms interact and how
their relative expression levels are controlled will give a deeper
insight on staphylococcal pathogenesis, and support to the design
of new therapies against this important human pathogen.
MATERIALS AND METHODS
Strains and Growth Conditions
Staphylococcus aureus strains used in this study are listed in
Supplementary Table S1. Staphylococcal strains were grown at
37◦C in trypticase soy agar (TSA) plates supplemented with
5% (v/v) of sheep blood or tryptic soy broth (TSB, Difco
Laboratories) at 37◦C. Growth curves for each of the analyzed
strains were performed to define the OD corresponding to the
different growth phases. The ODs identified were OD = 0.5 for
early exponential phase, OD = 2.0 for mid-exponential phase,
OD = 4.0 for late exponential phase, OD = 8.0 for early stationary
phase, OD = 10.0 for late stationary phase; a representative
timecourse is shown in Supplementary Figure S1. Escherichia
coli DH5α clones were grown at 37◦C on LB plate or LB broth,
supplemented with 100 µg ml−1 of ampicillin when required.
Western Blot Analysis
Staphylococcus aureus cell wall-associated protein samples were
prepared as already described (Corrigan et al., 2009), using
liquid growth of OD600 = 0.6. The total protein content of
the preparation was measured by the Bradford colorimetric
method according to manufacturer’s instructions and equal
protein amounts were loaded onto a 4–12% Bis-Tris gel, and
transferred to nitrocellulose membrane using the iBlot transfer
device (Thermo Fisher Scientific). For SpA detection, the
membrane was incubated with SpA-specific chicken antibodies
conjugated with biotin and revealed with HRP-conjugated
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streptavidin. Alternatively, SpA was detected as previously
reported (O’Halloran et al., 2015), probing the membrane with
HRP-conjugated rabbit anti-mouse IgG (1:2,000 Dako).
Genomic DNA Extraction, Sequencing
and Assembly
Genomic DNA was extracted from overnight bacterial growth
using GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich)
according to manufacturer’s instructions. Sequencing was
performed with HiSeq 2500 Sequencing System from Illumina
and Paired-Ends. Paired reads were assembled using CLC
genomic work bench (Qiagen). Comparative analysis was
performed using BRIGG software and N315 genome as reference.
Alignments of specific DNA regions were performed with
MUSCLE algorithm in Geneious software (Biomatters).
spa Promoter Reporter System
The promoter and the 5′UTR of spa gene were fused to mCherry
in a pOS1 plasmid backbone (Supplementary Table S2).
The primers (Supplementary Table S3) NWMN_0055_-
266_EcoRI_F/NWMN_0055_-1_R were used to amplify a
sequence of 265 bp upstream of the spa start codon from Newman
genomic DNA, which includes the spa promoter, the 5′UTR
region and start codon, while StamCh.R/StamCh.F primers
were used to amplify the mCherry gene. The two amplicons
were fused through fusion PCR using the complementary
sequences of StamCh.F and NWMN_0055_-1_R. The resulting
fusion of spa promoter and 5′UTR-mCherry was cloned into
the pOS1 vector using EcoRI-PstI restriction sites generating
the pOS1pspA. The pOS1pspA was modified to obtain the
variant of the spA promoter lacking the RBS by whole plasmid
PCR. The primers RBS_KO_pspA_F and RBS_KO_pspA_R
carrying the RBS mutation were designed to anneal on the
region to be modified. The PCR product was digested with
DpnI and transformed into E. coli DH5α competent cells and
several clones were sequenced to identify the plasmid containing
the mutation, named pOS1pspARBS. DH5α clones carrying
the empty pOS1 plasmid, the wt promoter 5’UTR-mCherry
fusion and the variant containing the RBS mutation were grown
overnight in LB + 100 µg/ml ampicillin, and fluorescence
was excited at 584 nm and measured at 610 nm in three
independent experiments.
RNA Extraction and cDNA Synthesis
Samples for RNA extraction were collected from S. aureus isolates
grown in liquid to the needed growth phase and stabilized
using RNAprotect Bacteria Reagent (QUIAGEN, Germany). The
bacterial pellet was resuspended in 1ml of Trizol reagent (Thermo
Fisher Scientific) and lysed in a FastPrep R©-24 homogenizer (MP
Biomedicals). The RNA was purified using the PureLink kit
(Ambion) applying an on-column DNase digestion step using the
RNase-free DNase kit (QIAgen) according to the manufacturer’s
instructions. Residual DNA was removed by a second DNase
treatment using RQ1 DNase (Promega) followed by a second
RNA purification using the PureLink kit. cDNA synthesis was
performed with SuperScript First-Strand Synthesis System for
RT-PCR (Thermo Fisher Scientific), using random hexamer
primer for reverse transcription (RT).
Virulence Factor Transcription Profile
The virulence factors transcript profile was assessed using the
high-throughput qRT-PCR system BIOMARK HD (Fluidigm),
with 84 specific TaqMan assays (Supplementary Table S4).
Two Chips containing different sets of assays were used, both
containing two technical replicates of the housekeeping gene
gyrB. gyrB was used as housekeeping reference gene, and each
assay was normalized to the mean of the gyrB replicates for
each Chip. For the transcription kinetic profiles, all the samples
were normalized to the early stationary phase using the 11ct
method. Clusterization of genes or samples was performed using
the Multiple array viewer (Mev) application with Hierarchical
Clustering, Pearson correlation as distance metric.
Comparative transcriptional analysis between SpA+ and
SpA− strains was performed using GraphPad Prism 7 software as
follows: the difference between mean1ct for the SpA+ and SpA−
strains was calculated for each gene at each time point; two-way
ANOVA was used to establish the significance of the difference,
comparing values at same time points, and correcting for multiple
comparisons by Sidak correction.
qRT-PCR
qRT-PCR was done using Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen–Life Technologies) and ROX as
internal control on a STRATAGEN Mx3000P QPCR system.
Final data were analyzed with the 11ct method, normalizing
samples to the expression levels of gyrB. The statistically
significant difference between SpA+ and SpA− strains was
determined by unpaired t-test with Welch’s correction using
GraphPad Prism 7 software.
Capsule Immunoblot
Staphylococcus aureus isolates were grown to OD600 = 12.0, and
then pelleted. The bacterial pellets were resuspended in 0.5%
SDS (v/v), 5 mM DTT, 100 mM Tris (pH = 8) and treated with
proteinase K for 1h at 45◦C. Serial dilutions were loaded onto
a nitrocellulose membrane. The membrane was blocked with
PBS-Milk 10% (w/v) Tween20 0.05% (v/v) and then incubated
with CP5-specific rabbit antiserum, followed by goat anti-rabbit
HRP. The blots were developed using the Pierce ECL Western
Blotting substrate (Thermo Fisher Scientific), the images were
acquired using Chemidoc (BIO-RAD) and dot intensities were
defined using Imagelab (BIO-RAD). The statistically significant
difference between SpA+ and SpA− strains dot intensities was
determined by unpaired t-test with Welch’s correction using
GraphPad Prism 7 software.
Phagocytic Uptake Experiment
Phagocytic uptake was measured similarly to the protocol
already described by Nordenfelt et al. (2012). Overnight cultures
were fixed in 1% (v/v) paraformaldehyde and counted by flow
cytometry. Fixed bacteria were stained for 15 min with FM-64fx
stain and washed in PBS. 107 stained bacteria were incubated
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with rabbit anti capsule serum, 1% (v/v) guinea pig complement
and 106 HL60 differentiated cells for 30 min in the dark. Samples
were washed in PBS and fixed in 1% (v/v) paraformaldehyde for
20 min, then washed in PBS and incubated in PBS 1% (w/v)
BSA and 1:100 anti-S. aureus polyclonal antibodies (Thermo
Fisher) for 1 h. After a wash in PBS 1% (w/v) BSA, the samples
were incubated in Rhodamine (TRITC) F(ab′)2 Fragment Goat
Anti-Rabbit IgG (Jackson Immunoresearch), for 30 min. After a
wash in PBS 1% (w/v) BSA and a second wash in PBS, the samples
were resuspended in PBS and read with flow cytometry with
BD LSRII (BD Biosciences). Neutrophils with only internalized
bacteria were gated selecting for FM-64fx positive and TRITC
negative events. For each sample, 10,000 events were analyzed
using FlowJo software. In each sample, the delta geometric
mean of the positive and negative populations was multiplied
by the percentage of positive neutrophils, giving an estimate
of the bacteria internalized for each sample. The results were
analyzed using a two-way ANOVA implemented in GraphPad
prism 7 software, comparing each condition −S −C within
each strain to the control, and applying Sidak correction for
multiple comparisons.
RESULTS
Identification of a Small Subset of
Strains Not Expressing SpA
Our first aim was to evaluate the presence of the spa gene and
its expression in a collection of S. aureus strains. The collection
was composed of 133 strains, including commensal and clinical
isolates from diverse niches and different geographic origin as
well as some lab strains, and categorized by Multilocus sequence
typing (MLST) (Figure 1A). The collection included strains
belonging to 33 different sequence types (ST) (Figure 1A), of
which the largest portion was composed of ST5 (39 isolates) and
ST8 (20 isolates), which are the most common types globally,
FIGURE 1 | SpA expression screening in a large panel of strains. (A) Lineages represented in the S. aureus collection. The majority of the strains belong to CC5 and
CC8 lineages. (B) SpA expression in a representative panel of strains. Western blot analysis on the SpA- strains and the representative panel of SpA+ strains.
Samples were taken from the exponential phase of in vitro grown cultures, SpA was detected by direct binding with rabbit anti-mouse antibody conjugated to HRP.
Western blots on cell wall preparations stained with anti-SpA chicken antibody having specificity for SpA, and anti-mouse rabbit antibody conjugated to HRP
capable of binding to all Ig-binding proteins, reveal similar signals (data not shown) and indicate that SpA is the only Ig-binding protein detected in these fractions.
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and also ST30 (10 isolates), ST105 (6 isolates), ST15 (4 isolates),
and ST 188 (4 isolates). The rest of the collection included
sequence types represented by lower numbers of isolates. The
collection was tested by PCR for the presence of the spa gene,
and by Western blot for the expression of the SpA protein
using a chicken anti-SpA antiserum. Although all the strains
carried the spa locus (data not shown), nine of them resulted
negative in Western blot analysis (Figure 1B). The SpA negative
(SpA−) strains include members of clonal complex (CC) 5: Mu50
(Hiramatsu et al., 1997), four strains isolated in United States
(MB01, MM1, MM2, and S27), two isolates from Italy (ITSA18
and ITSA19); and two laboratory strains belonging to CC25,
Lowenstein (ATCC 49521) and Reynolds (Fournier et al., 1987).
Figure 1B shows the Western blot for SpA expression in cell
wall preparations in SpA− strains as well as an equal number
of SpA+ representative strains from CC5, in particular, strain
N315 (Kuroda et al., 2001), four strains isolated in United States
and four strains isolated in Italy. No SpA was detected in the
supernatants of the SpA- strains by Western blots (data not
shown), suggesting that no SpA is expressed in these strains.
N315 and Mu50 are well characterized USA100 lineage strains
isolated in Japan in 1982 and 1998, respectively (Hiramatsu et al.,
1997). Their genomes were previously sequenced and compared,
showing 96% of sequence identity (Kuroda et al., 2001; McDougal
et al., 2003; Bonnstetter et al., 2007). Given their well-established
characterization, Mu50 and N315 were chosen as representatives
for the SpA− and SpA+ group, respectively.
A Deletion in the spa 5′UTR Affects
Protein Production in a Subset of
SpA− Strains
After the identification of the SpA− phenotype in a subset
of strains, we investigated the possible reasons for the loss of
SpA expression. In particular, we investigated if at the level
of genome sequence, we could identify a genetic basis for the
SpA− phenotype that could be shared by the different SpA−
strains. For this purpose, we analyzed the genomes of the eight
United States strains (United States sub panel in Figure 1B),
in addition to N315 and Mu50. Comparative genomic analysis
showed that all the strains shared high sequence identity when
compared to N315 (Figure 2A). As expected, Mu50 resulted
with higher similarity to the N315 genome, while S27 is the
isolate that carries the highest number of mutations. Most of
the identified mutations are present in all the United States
isolates, suggesting that these mutations are not responsible for
the phenotype. It was not possible to identify a single nucleotide
polymorphism or indel carried by all the SpA− strains and not
present in any of the SpA+. However, three of the SpA− strains
(MB01, MM1, and MM2) showed a deletion of eight nucleotides,
six nucleotides upstream of the spa start codon (Figures 2B,C).
The sequence corresponding to the deletion (CAGGGGGT) and
its position make it likely to contain a Ribosome Binding Site
(RBS) sequence for the spa gene. Further analysis on the spa
locus showed some additional differences among the isolates
(Figure 2B). The spa gene in Mu50 and N315 carries a deletion of
174 nucleotides, which corresponds to one IgG binding domain
and whose expression results in a shorter version of the protein,
as already shown in the Western blot (Figure 1B). S27 isolate
carries several SNPs across the sequence as well as a shorter X
variable region. Most of these mutations are silent, and none of
these is responsible for an early stop codon. In order to investigate
whether the deletion found in the UTR of three of the SpA− strain
could be responsible for their SpA− phenotype, we generated two
translational fusions of the spa promoter and 5′UTR region to an
mCherry reporter expression system with or without the deletion.
While the expression of the reporter was detected when the N315
spa gene upstream sequence was fused to mCherry, fusion of
the sequence containing the deletion resulted in no fluorescence
signal, confirming that this deletion is responsible for abolishing
SpA expression in the three identified strains (Figure 2D). This
genomic analysis showed that the genetic reasons for SpA−
phenotype are probably different among the different strains, but
for three of them the loss of SpA expression can be attributed to
a mutation in the spa 5′-untranslated region.
Comparative Transcript Profiling of a
Large Panel of Virulence Related Genes
in SpA+ and SpA− Strains
Our genomic analysis showed that the genetic bases for the SpA−
phenotype are probably different among the different strains.
For this reason, the SpA− strains were further investigated using
a high-throughput qRT PCR approach to perform comparative
transcription profiling. A panel of 83 virulence related genes
was selected to include factors expressed in different stages
of staphylococcal infection, including adhesion, invasion and
immune evasion. It is known that virulence genes exhibit
in vitro growth phase regulation (Cheung et al., 2004), therefore,
we performed the transcriptional profiling by measuring the
transcript levels of the 83 virulence related genes at five
representative time points of the growth curve (early, mid
and late exponential phases, early and late stationary phases).
The heatmap (Figure 3) shows the transcription kinetics of
the selected genes in all the strains tested. All genes were
clustered according to their transcription profiles through the
growth curve and among the isolates. Notably, expression for
the majority of the genes is increased with respect to early
log phase (absorbance at 600 nm = 0.5) as indicated by the
yellow predominance in the heatmap. There are five main
clusters representing different transcript kinetic profiles, which
are represented in Supplementary Figure S1. Cluster 1 comprises
the genes whose transcription decreases during growth like clfB
and fnbB (Figure 3 and Supplementary Figure S1) (Mader et al.,
2016). Cluster 2 includes the genes which are upregulated in
mid-exponential phase and then downregulated in stationary
phase. This second cluster contains isdA, isdB, isdC, and isdG
genes, which are part of the iron-regulated surface determinant
pathway (Skaar and Schneewind, 2004) as well as sirA, which
encodes for an iron-regulated lipoprotein involved in iron
metabolism (Heinrichs et al., 1999), suggesting that this cluster
could represent genes that respond to iron availability (Figure 3
and Supplementary Figure S1). The genes comprised in Cluster
3 are highly upregulated as growth progresses. As expected,
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FIGURE 2 | Genetic differences of SpA+ and SpA- strains. (A) Comparative genomic analysis using N315 as reference (inner circle). The figure shows the genetic
identity between the strains and the N315 reference strain. The SpA+ strains are depicted in orange, the SpA- strains in blue. White gaps show regions present in
the reference strain but absent in the analyzed genomes. The analyzed strains are, from the inner circle to the outer circle, N315, CI398, CI683, CI709, CI755, Mu50,
MB01, MM1, MM2, and S27. (B) Alignment of spa locus in the subset of strains. The upper bar highlights the sequence identity of the spa locus. The yellow arrow
shows the position and orientation of the spa coding sequence. The black bars represent the sequence in each strain and the gaps correspond to deletions.
(C) Magnification of the region upstream of the coding sequence of spa. The start codon is highlighted in green and the mismatch present in the MB01 sequence is
highlighted in yellow. The dashed gaps underline the deletion present in the 5′UTR region of the spa gene in MB01, MM1, and MM2 strains. (D) Effect of the 5′ UTR
mutation on reporter production. The graph shows the fluorescence signal obtained from overnight growth of E. coli transformed with pOS1 plasmid containing
either the wt spa promoter, or carrying the RBS mutation fused to mCherry reporter gene. The empty vector control shows the signal from E. coli strain transformed
with pOS1 backbone. The graph represents three independent experiments from different clones and statistical significance was calculated by an unpaired t-test
with Welch’s correction, ∗∗∗p < 0.001.
this cluster includes genes involved in the quorum sensing
system agr, such as agrA and hld. In particular, agrA encodes
for the response regulator of the system, while the hld-coding
sequence is located on the RNAIII transcript, which is the
RNA effector molecule of the system (Haag and Bagnoli, 2017).
Several genes known to be targets of the agr system are
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FIGURE 3 | Virulence factors transcript levels variation during in vitro growth curve. Each column represents one assay, while each row corresponds to a sample.
Values are normalized to the first growth point (early stationary phase, OD 0.5). Genes transcribed at levels lower than the first growth point are depicted in blue,
up-regulated genes are in yellow. The bars on the two sides of the heatmap represent the five major clusters: cluster1 (green), cluster 2 (dark green), cluster 3
(yellow), cluster 4 (pink), cluster 5 (orange). Several assays were not able to detect target transcripts in the S27 isolate. This might have been caused either by a high
degree of mismatch between the probes and the target, or the absence of the target gene.
grouped in this cluster, like the capsule biosynthetic genes
capA and cap5H or the alpha-haemolysin hla (Figure 3 and
Supplementary Figure S1) (Dunman et al., 2001). The genes
in cluster 4 are moderately up-regulated during growth, except
for the N315 strain where they appear down-regulated (Figure 3
and Supplementary Figure S1). This is particularly evident
when comparing the mean kinetic profile of N315 with the
other strain (Supplementary Figure S1, cluster 4). Cluster 5
contains genes whose transcripts increase moderately during
growth. The spa gene is not present in any of these major
clusters, its transcription increases in mid exponential phase
and decreases during stationary phase, while its transcription
kinetics varies considerably among the isolates. The variability
of spa transcript in SpA− strains follows the upregulation of spa
itself, which has the highest expression in the exponential phase.
In Supplementary Figure S2, the spa transcription kinetics are
shown in detail for each strain, considering the different relative
steady state levels, and highlighting three different behaviors.
Two of the strains with the RBS mutation (MM1 and MM2)
maintained a similar profile of expression of the SpA+ strains,
even though at lower steady state levels in comparison with
SpA+ strains. Strains MB01 (that harbors the RBS mutation)
and S27 maintained this profile only partially, as reflected by the
flatter curve. Mu50 shows a completely flat trend, with similar
transcript levels across the growth. This means that some of the
SpA− strains lost spa regulation during growth and expressed
lower steady state spa transcripts.
To highlight the transcriptional differences between SpA+ and
SpA− strains, we calculated the difference in gene expression
between the mean RNA levels of SpA+ and SpA− strains. The
genes were ranked based on their up-regulation in one or the
other group and plotted in a heatmap (Figure 4A). Present at
the two extremities of the heatmap are the genes that were
differently expressed in each point of the growth, i.e., genes that
are always upregulated in one group or the other. The center
of the heatmap contains some of the genes that had different
transcript levels between the SpA+ and SpA− strains in specific
growth phases. The significance of the difference in the amounts
of transcripts for each gene was assessed through a two-way
ANOVA, as shown by the volcano plot in Figure 4B. This
analysis highlighted five genes that show significant differences in
transcript levels between the two groups of strains, i.e., a twofold
level or higher and a p-value lower than 0.05. As expected, the
spa gene exhibits the highest upregulation in the SpA+ strain,
while other two genes, sdrC and sasD, were upregulated in
SpA+ strains with lower significance. Interestingly, two genes
were upregulated in the SpA− strain, the capsule biosynthesis
related genes capA and cap5H. These two genes belong to the
capsule biosynthesis operon and are the first gene of the operon
(capA) and the first gene in the capsular polysaccharide type 5
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FIGURE 4 | Comparative transcription profile between SpA+ and SpA- strains. (A) The heatmap shows the difference between the mean RNA levels of SpA+ and
SpA- strains at each time point for each gene. The genes that are more transcribed in the SpA+ strains are depicted in yellow, while the ones that are more
transcribed in the SpA- strains are depicted in blue. (B) Volcano plot showing genes with significant difference in transcription. For each assay, a two-way ANOVA
was performed testing the difference in transcription between SpA+ and SpA- strains through the different growth points. Genes are displayed according to the
mean difference in transcript levels between SpA+ and SpA- strains along the entire growth, and the p-value measuring the associated statistical significance. On
the right, with positive mean difference, the genes that are more transcribed in the SpA+ strains; on the left, with negative mean difference, the genes that are more
transcribed in the SpA- strains. (C) Transcription trends for spa, capA, and cap5H. The boxplots show the transcription of the three genes in the SpA+ and SpA-
strains; bars show the median values, whiskers the maximum and minimum values. The values are normalized by the mean of the SpA+ strains at OD 0.5. The
dotted line represents the SpA+ mean level in early exponential phase.
specific region (cap5H), respectively (Sau et al., 1997). Notably,
in the S27 isolate the cap5H transcript was not detected, and
genome sequencing revealed a divergent sequence of the capsule
biosynthetic locus, indicating that this strain most likely belongs
to a different serotype. The boxplots in Figure 4C show in
more detail the transcriptional changes of spa, capA, and cap5H
during growth. As already reported, spa is upregulated during
the exponential phase, while capsule biosynthetic genes are
progressively upregulated during growth and mostly transcribed
during stationary phase (Mader et al., 2016). With this analysis we
identified five genes differentially transcribed between the SpA+
and SpA− groups, including the upregulation of the capsule
biosynthesis operon in SpA− strains.
Regulatory Network Analysis of Genes
With Distinct Transcription Profiles in
SpA+ and SpA− Strains
The known regulators of the genes with a significant difference in
transcript levels between SpA+ and SpA− strains were extracted
from the SATMD S. aureus Transcriptome Meta-Database
(Nagarajan and Elasri, 2007), and are shown in Figure 5.
Three different types of genes can be identified in the
regulatory network. Seven genes (Figure 5, group marked
1) are known to have similar regulatory activity on both
groups of genes upregulated in SpA+ or SpA− strains,
indicating that they are unlikely involved in the SpA−
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FIGURE 5 | Regulatory network of genes differentially transcribed between SpA+ and SpA-. The network was extracted from the SATMD Database. The yellow
circles represent genes upregulated in SpA+ strains, the blue circles represent the genes upregulated in the SpA- strains. The color intensity represents the
magnitude of upregulation in one group of strains or the other. The dimension of the circles is proportional to the -log10 of the p-value of the ANOVA testing
upregulation between SpA+ and SpA- strains. Green circles represent genes, or combination of genes, whose deletions influence the transcription of the five genes
of interest. The three regulators present in the assays are depicted with the same graphic representation of the differential transcribed genes. Red arrows represent a
positive regulation, blue arrows a negative regulation. Dotted lines represent interaction not found in the database, but in the literature. (1) Regulatory genes that
influence in both groups of genes transcription, which is not consistent with transcript analysis. (2) Regulatory genes that exert on both groups of genes a regulation
consistent with transcript data.
phenotype. Twenty genes were shown to influence the
transcription of only one of the two groups of differently
expressed genes, implying that one single gene of this
group cannot be responsible for SpA− phenotype. Ten
of the regulators (stk1, ccpA, traP, mgrA, agr, sarA, rot,
ecsA, codY-agr, and nsaRS; Figure 5, group marked 2)
are reported to have an opposite regulatory activity on
the genes identified as having distinct profiles in SpA+
and SpA− group of strains. This suggests that a shift in
the regulatory output of one of these regulators could
result in the transcriptional differences observed in the
SpA− strains.
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Capsule Gene Transcription and Capsule
Production Is Higher in SpA− Isolates of
Geographically Distinct Origin
Having identified significant transcriptional differences in the
United States subset of strains, we expanded the subset to
include the remaining SpA− strains as well as a control SpA+
group to verify the upregulation of capA and cap5H transcripts
by qRT-PCR, and quantified the relative amount of capsule
produced by all strains. The capA and cap5H transcript levels
were quantified at a single time point by qRT-PCR. As already
observed, the RNA levels of both genes were significantly higher
in the SpA− strains (Figure 6A). To quantify the amount of
capsule produced by the SpA− strains, we performed a capsule
immunoblot from a single growth point (Figure 6B). The
analysis showed high variability in the amount of capsule among
the different strains, but the highest capsular polysaccharide
amount was detected in the SpA− isolates. Moreover, four of the
SpA+ strains (N315, CI709, ITSA6, and ITSA14) produced no
detectable capsule at the time point tested, while all SpA− strains
expressed capsule at detectable levels.
SpA− Strains Are Susceptible to
Phagocytosis Mediated by
Capsule-Specific Antibodies
After we gained evidence of the fact that SpA− and SpA+ strains
produce different amounts of capsule, we explored whether the
capsule produced by the SpA− strains was enough to elicit
neutrophil uptake in the presence of capsule-specific antibodies.
N315 and Mu50 were used as SpA− and SpA+ reference strains
and a phagocytosis experiment was set up using capsule-specific
rabbit antisera as described in Section “Materials and Methods.”
Phagocytic uptake was visualized by confocal microscopy and
quantified by Flow cytometry. Figure 7A shows representative
examples of the interaction between Mu50 and neutrophils in
different conditions. In the absence of complement and serum,
no bacteria were associated with neutrophils. The presence of
both complement and specific serum lead to the interaction
of all the bacteria with the neutrophils, with almost complete
phagocytic uptake. The effect of different serum dilutions and the
presence or absence of complement source were tested on both
Mu50 and N315 strain (Figure 7B). The minimal level of uptake
observed in absence of either complement or serum was used as
baseline level for both strains. In the case of Mu50, the addition
of the capsule-specific serum alone induced the internalization
of the bacteria in a dose-dependent manner, while with N315
the phagocytic uptake remained similar in either presence or
absence of serum. The presence of complement alone determined
an increased uptake for both strains, but higher in Mu50: this
is probably due to a reduced susceptibility to phagocytosis in
the absence of complement of the encapsulated strain (Nilsson
et al., 1997). The addition of both specific serum and complement
again strongly increased the uptake of the Mu50 strain but not
of the N315. As N315 expresses high levels of SpA, to test
that the lack of capsule-mediated opsonophagocytosis was not
due to the anti-phagocytic activity of SpA, we produced an
SpA mutant and determined that no difference was observed in
the presence or absence of SpA in this strain (Supplementary
Figure S3). With these experiments, we confirmed that SpA−
strains express higher quantities of capsule, and that this capsule
amount is enough to elicit phagocytosis in presence of capsule
specific antibodies.
DISCUSSION
This study aimed to investigate the expression of SpA, both
virulence factor and recently proposed vaccine antigen, and
its interplay with other virulence determinants. Despite the
important role of SpA in staphylococcal pathogenesis, the
screening of a library of strains allowed us to identify a
subset of strains lacking SpA expression (SpA−). The molecular
mechanisms that determine the SpA− phenotypes were found
to be different among the SpA− strains and involve both RNA
translation in the three SpA− strains that lacked a functional
spa RBS, and likely alterations in the transcriptional network.
FIGURE 6 | Capsule biosynthesis operon transcription and capsule production in SpA+ and SpA- strains. (A) capA and cap5H transcript levels in SpA+ and SpA-
strains. (B) Capsule production in SpA+ and SpA- strains. Bars indicate the medians, whiskers the maximum and minimum values. All values are relative to the
mean of SpA+ strain levels. Statistical significance is calculated with Welch’s t-test, ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
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FIGURE 7 | Effect of capsule specific serum on Mu50 phagocytosis. Fixed bacterial cells were incubated with differentiated HL60 cells in the presence or absence of
a source of complement and capsule-specific antiserum. (A) Confocal microscopy visualization of phagocytosis experiments. DAPI stain binds DNA and shows
neutrophil nuclei and bacterial cells (with lower intensity). Total bacteria are shown by the staining after cell permeabilization, extracellular bacteria are shown by the
staining before cell permeabilization. (B) Effect of capsule specific antiserum on SpA+ and SpA- phagocytosis. The graph shows the fluorescence associated to
neutrophils after phagocytosis of fluorescent stained bacteria, under different conditions. The phagocytosis was performed in absence of both serum and
complement (–S –C), in absence of complement and in presence of different serum dilutions (S –C), in absence of serum and in presence of inactivated complement
(IC), in absence of serum and in presence of complement (–S +C), or in presence of both complement and different dilutions of serum (S +C). Each experiment was
normalized by the corresponding –S –C sample. The experiment was performed in triplicate, the error bars show the standard deviations. The graph reports the
results of multiple comparisons obtained with a two-way ANOVA, in which each condition was compared to the –S –C reference sample. p-values are indicated as
∗∗p < 0.005, ∗∗∗p < 0.0005; ns, not significant.
The different kinetic profiles of the spa transcript in the SpA−
strains, showing lower steady state levels and lower or completely
absent growth phase regulation, indicate that there are several
independent factors influencing spa transcription and causing the
loss of SpA expression in these strains.
Through transcriptional profiling of a large number of
virulence determinants, the major differentiating factor identified
between SpA+ and SpA− strains is the upregulation of the
capsule biosynthesis operon in the SpA− strains. It is important
to notice that these differences are not the only transcriptional
changes occurring in the SpA− strains but represent a major
relevant characteristic that is shared by all the SpA− strains,
suggesting that capsule upregulation is a common correlated
adaptation. Two other genes, sasD and sdrC, encoding cell
wall anchored proteins, were identified as downregulated in
the SpA− strains.
The regulators shared by spa, sdrC and sasD (walR, sarA,
agr, and nsaRS) are known to effect the same regulatory
activity on those three genes, confirming that they are part of
a similar regulatory network. Conversely, the analysis of the
factors influencing spa and capsule transcription showed that
several regulators (sarA, agr, mgrA, traP, ccpA, rot, ecsA, and
nsaRS) determine opposite effects on these two virulence factors,
indicating that multiple systems closely control inverse regulation
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to balance the expression of capsule and SpA. Alterations in
any one of these factors involved in maintaining this balance
would lead to the inverse shift that we observed between
the SpA− strains.
This inverse regulation could be necessary due to the common
localization of SpA and capsule on the cell surface and the
somewhat redundant nature of their functions, especially in
relation to evading opsonophagocytosis. Risley et al. (2007)
showed how the presence of capsule on the bacterial surface
masks another major surface protein Clumping factor A (ClfA)
and, probably due to steric hindrance, inhibits its binding to
fibrinogen. Moreover, Nanra et al. (2013) demonstrated that,
in strains expressing both capsular polysaccharide and SpA,
protein A does not elicit an anti-phagocytic effect toward
anti-capsule specific antibodies, suggesting that capsule may
interfere with SpA functions. Importantly, the fact that the SpA−
phenotype has occurred repeatedly through diverse mechanisms
in geographically distinct locations, suggests that the loss of
SpA expression may represent the response to a selective
pressure under specific conditions. Moreover, multiple examples
have been reported of adaptive responses where SpA and
capsule expression are inversely altered. For example, lower
SpA expression and higher capsule production are common
phenotypic features in Vancomycin Intermediate S. aureus
(VISA) strains (Kuroda et al., 2000; McAleese et al., 2006;
Howden et al., 2008; Gardete et al., 2012; Jansen et al., 2013).
VISA strains acquire resistance through several cumulative and
reversible mutations, allowing the bacteria to reduce vancomycin
susceptibility through an increased thickness of the cell wall
(Gardete et al., 2012; Howden et al., 2014; Hu et al., 2016;
McGuinness et al., 2017). Through our regulatory network
analysis, the regulators identified as ‘fitting’ the observed
SpA+/SpA− regulatory effects, namely vraSR, walRK, stk1, stp1,
rpoB, clpP, are involved in cell wall biosynthesis and often
involved in VISA strains (Hu et al., 2016). While the SpA−
strains analyzed in this study do not exhibit significant increase
in vancomycin resistance (data not shown), the overexpression
of capsule in strains lacking SpA is a feature shared with that of
the VISA phenotype.
Several studies based on both clinical or laboratory evidences
reported that VISA strains are associated with reduced virulence
(Majcherczyk et al., 2008; Horne et al., 2009; Peleg et al.,
2009; Lalueza et al., 2010) and are less likely to cause acute
clinical manifestation but more likely to be persistent (Cameron
et al., 2011, 2017). It was proposed that the phenotypic
features of VISA strains may be the consequences not only of
antimicrobial treatment, but also of changes in host pathogen
interactions, prompting a combined resistance and persistent
phenotype (Howden et al., 2008; Gardete et al., 2012). Another
staphylococcal phenotype associated to persistence is the small
colony variant (SCV) phenotype (Cameron et al., 2011). In a
recent comparative transcriptome study, we observed that a
strong increase in capsule gene transcription and lower spa RNA
in the SCV clones compared to parental strains is evident in
their dataset (Chen et al., 2018). The presence of this common
expression pattern in different clinically relevant phenotypes
of S. aureus drives the hypothesis that the balance of SpA
and capsule is a crucial feature in staphylococcal adaptation.
Moreover, it is interesting to note that despite the changes
in expression of these two virulence factors, their coding
sequences are not affected by major mutations, suggesting that
the bacterium may be able to switch from SpA+ to SpA−
phenotype and vice versa to adapt to different conditions. It is
worth noting that the SpA− isolates that we identified from 2
geographically distinct sets of clinical isolates belong to the CC5
lineage associated with HA-MRSA strains, suggesting that the
adaptation to a SpA− phenotype may occur preferentially in
hospital acquired infections.
In the context of vaccine research, this peculiar balance is
of major relevance when using prophylactic strategies targeting
one of these two major virulence factors, SpA or capsule. In
particular, intervention strategies targeting solely SpA may not
be successful against all strains as SpA− strains are found to
arise independently in distinct geographical locations. Here, we
show that a SpA− strain is highly susceptible to the opsonic
effect of anti-capsule antibodies, therefore suggesting that an
intervention/vaccine strategy targeting both factors could be used
for extending the coverage of SpA antigen to the broadest number
of staphylococcal strains.
A vaccine strategy using capsular polysaccharide as unique
antigen was already developed but failed in phase III clinical trial
(Fattom et al., 2004, 2015). One of the reasons of the capsule-
based vaccine failure could be the emergence of strains with
no or low capsule expression, as we have shown that SpA+
strains may not be susceptible to capsule specific antibodies. In
particular, the USA300 lineage, which in the past years became
the predominant epidemic CA-MRSA strain in United States,
was shown to lack the capsular polysaccharide due to conserved
mutations in the capsule biosynthetic operon (Boyle-Vavra
et al., 2015). The development of anti-staphylococcus therapeutic
antibodies directed toward SpA is currently in clinical trials
(Holland et al., 2018). The presence of a widespread number
of strains that differs in virulence, and the development of
several phenotypes through the adaptation to the host, suggest
that a multicomponent strategy is fundamental in staphylococcal
vaccine design. From this study, we have determined that SpA
and capsule antigens could be targeted by either passive or
active immunization as vaccine approaches to effectively target
a broader range of strains with phenotypic adaptations involving
different virulence determinants.
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FIGURE S1 | Kinetic profiles of the four major transcription clusters. Black lines
represent the mean values of single genes and the error bars show the standard
deviation among the isolates. The mean profile of the genes within the cluster is
showed in pink. In cluster 4, the blue line represents the mean of the
cluster in N315 strain.
FIGURE S2 | spa transcript profiles in all the SpA+ and SpA− strains. The black
lines indicate the transcript profile of the SpA+ strains, while the colored ones
represent the spa RNA levels in the SpA− strains. All the values are normalized to
the mean of the SpA+ strains in the early exponential phase. The three strains that
carry the RBS mutation are highlighted in the figure legend.
FIGURE S3 | Lack of capsule-mediated opsonophagocytosis in N315
background is not due to anti-phagocytic activity of SpA. The graph shows the
fluorescence associated to neutrophils after phagocytosis of fluorescent stained
bacteria, under different conditions. The phagocytosis was performed in absence
of both serum and complement (–S –C), in absence of complement and in
presence of different serum dilutions (S –C), in absence of serum and in presence
of inactivated complement (IC), in absence of serum and in presence of
complement (–S +C), or in presence of both complement and different dilutions of
serum (S +C). Each experiment was normalized by the corresponding –S –C
sample. The experiment was performed in triplicate, the error bars show the
standard deviations.
TABLE S1 | Strains used in this study.
TABLE S2 | Plasmids used in this study.
TABLE S3 | Oligonucleotides used in this study.
TABLE S4 | TaqMan assays used in this study.
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